3.5 Executive Committee

Composition and functioning of the Executive Committee

During 2018, the composition of the Executive Committee was as follows:

Jean-Christophe Tellier

Chief Executive Officer

Jean-Christophe Tellier

Chief Executive Officer

1959 – French

Joined UCB in 2011

Appointed in 2011

Appointed CEO in 2015

Main external appointments

  • Vice-President and President Elect of the Board of EFPIA (European Federation of Pharmaceutical Industries and Associations)
  • Chairman of the Innovation Board Sponsored Committee (EFPIA)
  • Chairman of the IMI (Innovative Medicines Initiative) Governing Board
  • Member of the Board of PhRMA (Pharmaceutical Research and Manufacturers of America)
  • Member of the Board of WELBIO (Walloon Institute for Life Lead Sciences)

Experience

Over 25 years in the pharmaceutical sector, with Ipsen and Novartis where he held several senior executive positions

Emmanuel Caeymaex

Executive Vice President & Immunology Patient Value Unit Head

Emmanuel Caeymaex

Executive Vice President & Immunology Patient Value Unit Head

1969 – Belgian

Joined UCB in 1994

Appointed in 2015

No external appointments

Experience

Over 20 years of experience in biopharmaceuticals marketing and sales, general management and global project leadership

Jean-Luc Fleurial

Executive Vice President & Chief Talent Officer

Jean-Luc Fleurial

Executive Vice President & Chief Talent Officer

1965 – French

Joined UCB in 2017

Appointed in 2017

No external appointments

Experience

Over 20 years of experience in building and implementing talent strategy across geographies and businesses, mainly with Procter&Gamble and Bristol Myers Squibb

Iris Löw-Friedrich

Executive Vice President Chief Medical Officer & Head of Development and Medical Patent Value Practices

Iris Löw-Friedrich

Executive Vice President Chief Medical Officer & Head of Development and Medical Patent Value Practices

1960 – German

Joined UCB in 2006

Appointed in 2008

Main external appointments

  • Member of the Supervisory Board of Fresenius SE & Co. KGaA
  • Member of the Board of TransCelerate
  • Member of the Supervisory Board of Evotec AG

Experience

Physician, board-certified in internal medicine, with more than 20 years of experience in the development of medicines, with senior executive positions at Hoechst, Aventis, BASF Pharma/Knoll, Abbott and Schwarz Pharma

Alexander Moscho

Executive Vice President & Chief Strategy Officer

Alexander Moscho

Executive Vice President & Chief Strategy Officer

1970 – German

Joined UCB in 2017

Appointed in 2017

Main external appointments

  • Member of the Scientific Advisory Board of Adolphe Merkle Institute Fribourg

Experience

Over 20 years of global experience in the pharmaceutical, biotech and healthcare sector with Bayer and McKinsey, where he held senior executive positions in strategy and general management

Dhaval Patel

Executive Vice President & Chief Scientific Officer

Dhaval Patel

Executive Vice President & Chief Scientific Officer

1961 – American

Joined UCB in 2017

Appointed in 2017

Main external appointments

  • Member of the Board of Inflazome
  • Member of the Board of Anokion
  • Member of the Board of Kanyos Bio
  • Clinical Professor at University of North Carolina at Chapel Hill

Experience

Over 30 years of experience in R&D and immunology, more specifically with Novartis and in the academic world at Duke University Medical Center and the University of North Carolina

Pascale Richetta

Executive Vice President & Bone Patient Value Unit Head

Pascale Richetta

Executive Vice President & Bone Patient Value Unit Head

1959 – French

Joined UCB in 2016

Appointed in 2016

No external appointments

Experience

Over 20 years of experience in the pharma and biotech industry with Ipsen, GSK, Abbott and Abbvie

Anna S. Richo

Executive Vice President & General Counsel

Anna S. Richo

Executive Vice President & General Counsel

1960 – American

Joined UCB in 2012

Appointed in 2012

Left in January 2019

No external appointments

Experience

Over 27 years in the biopharmaceutical and medical device sectors with Amgen and Baxter Healthcare Corp., where she held several senior executive positions

Bharat Tewarie

Executive Vice President & Chief Marketing Officer

Bharat Tewarie

Executive Vice President & Chief Marketing Officer

1961 – Dutch

Joined UCB in 2015

Appointed in 2015

No external appointments

Experience

Physician, with more than 25 years’ experience in the pharma and biotech industry with Boehringer Ingelheim, F. Hoffman La Roche, Serono, EMD Serono and Merck Serono in several senior executive positions in the Netherlands, Germany, Switzerland and the U.S.

Detlef Thielgen

Executive Vice President & Chief Financial Officer

Detlef Thielgen

Executive Vice President & Chief Financial Officer

1960 – German

Joined UCB in 2006

Appointed in 2007

No external appointments

Experience

More than 25 years in the pharma industry with Schwarz Pharma and UCB, where he held several senior executive positions

Charl van Zyl

Executive Vice President & Chief Operating Officer

Charl van Zyl

Executive Vice President & Chief Operating Officer

1967 – British/South African

Joined UCB in 2017

Appointed in 2017

Main external appointments

  • Member of the Board of BIO (Biotechnology Innovation Organization)

Experience

Almost 20 years of experience across the healthcare value chain, including business development and licensing, manufacturing, marketing and sales and research & clinical development

Jeff Wren

Executive Vice President & Neurology Patient Value Unit Head

Jeff Wren

Executive Vice President & Neurology Patient Value Unit Head

1963 – American

Joined UCB in 2010

Appointed in 2015

No external appointments

Experience

Over 25 years in the pharmaceutical sector, with Sepracor (now Sunovian) and TAP Pharmaceuticals, in senior positions spanning sales and marketing, and managed markets

Xavier Michel, Group Secretary General, is acting as the secretary of the Executive Committee, ensuring the link between the Board of Directors, the Executive Committee and the broader organization.

Anna Richo, General Counsel & Head of Legal, IP and Ethics & Compliance left UCB for personal reasons with effect as from 2 January 2019.

The Executive Committee met on a regular basis with an average of 2-3 days a month in 2018.

There were no transactions or contractual relationships in 2018 between UCB, including its affiliates, and a member of the Executive Committee.

The functioning, competences and delegation of authority of the Executive Committee are further described in the Charter.

Honorary chairmen of the Executive Committee

The following directors have been nominated as honorary chairman of the Executive Committee:

  • Roch Doliveux
  • Georges Jacobs de Hagen
  • Daniel Janssen
  • Paul-Etienne Maes (†)